U.S. markets closed
  • S&P Futures

    4,306.25
    -1.50 (-0.03%)
     
  • Dow Futures

    34,116.00
    -2.00 (-0.01%)
     
  • Nasdaq Futures

    13,643.00
    -15.25 (-0.11%)
     
  • Russell 2000 Futures

    2,023.70
    +0.40 (+0.02%)
     
  • Crude Oil

    86.68
    +0.15 (+0.17%)
     
  • Gold

    1,790.80
    +1.10 (+0.06%)
     
  • Silver

    20.08
    -0.01 (-0.05%)
     
  • EUR/USD

    1.0177
    +0.0006 (+0.06%)
     
  • 10-Yr Bond

    2.8240
    +0.0330 (+1.18%)
     
  • Vix

    19.69
    -0.26 (-1.30%)
     
  • GBP/USD

    1.2110
    +0.0016 (+0.13%)
     
  • USD/JPY

    134.0800
    -0.1350 (-0.10%)
     
  • BTC-USD

    23,976.53
    -196.99 (-0.81%)
     
  • CMC Crypto 200

    570.75
    -1.16 (-0.20%)
     
  • FTSE 100

    7,536.06
    +26.91 (+0.36%)
     
  • Nikkei 225

    29,093.93
    +225.02 (+0.78%)
     

Tempest to Present at Two Upcoming Investor Conferences in November

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the following investor conferences in November:

  • Jefferies London Healthcare Conference – Company presentation available on-demand Thursday, November 18, 2021 at 8:00 a.m. GMT

  • Piper Sandler 33rd Annual Virtual Healthcare Conference – Fireside chat available on-demand Monday, November 22, 2021 at 10:00 a.m. ET

To access the live or archived recording of the company presentaions, please visit the investor section of the Tempest website at https://ir.tempesttx.com.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARα, respectively. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. In collaboration with F. Hoffman La Roche, TPST-1120 is also advancing through a first line, global, randomized Phase 1b/2 clinical study evaluating TPST-1120 in combination with the standard-of-care regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor Contact:

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Media Contact:

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com